Anika Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Anika Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
0.7×Over the last 3 years its own operating cash paid for 72% of its investment spending (capex); the rest came from other sources such as borrowing, cash reserves or new shares.
Higher than 67% of Healthcare companies in United States.
Cash Locked Ratio
$32For every $100 of sales, $32 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $57 tied up three years earlier.
More money tied up than 70% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
1/3 · 2/3Sales grew in 1 of the last 3 years; profit grew in 2 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales barely changed
Sales changed by -1% in 3 years, too little to measure extra profit per extra sales.
Asset Productivity Ratio
-1% / -46%In 3 years sales changed by -1% while total assets changed by -46%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
5.5×Debt due within a year is covered 5.5 times by its yearly operating cash.
Higher than 81% of Healthcare companies in United States.
Cash Cushion Ratio
+11%Cash, after subtracting all debt, equals 11% of its market value (net cash).
Higher than 52% of Healthcare companies in United States.
Tangible Assets Ratio
95%Of every $100 the company owns, $95 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 72% of Healthcare companies in United States.
Tangible Net Worth Ratio
93%Of every $100 of net worth, $93 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 77% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Anika Therapeutics, Inc. made a loss over the last year. Anika Therapeutics, Inc. owes $0.25 for every $1 it owns. Anika Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossAnika Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
2.06The share price is 2.06 times Anika Therapeutics, Inc.'s book value per share, lower than 58% of Healthcare companies in United States.
Market cap
$282 MThe total market value of all of Anika Therapeutics, Inc.'s shares at today's price (share price × number of shares), smaller than 53% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$137 MWhat Anika Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$10.26Net worth divided by the number of shares. The share price of $21.09 is 2.1 times this, which is the P/B above.
Return on equity (ROE)
-2.2%Anika Therapeutics, Inc. lost 2.2% of its shareholders' money over the last year, higher than 74% of Healthcare companies in United States.
Owes vs Owns
0.25×Anika Therapeutics, Inc. owes $0.25 for every $1 it owns (low), lower than 66% of Healthcare companies in United States.
Dividend yield
NoneAnika Therapeutics, Inc. does not currently pay a dividend.
Revenue growth
-6%Revenue fell 6% in the year to Dec 2025, and shrank 0% a year on average over 3 years.
Profit growth
LossAnika Therapeutics, Inc. made a loss in each of the last two years.
Profit margin
-9.6%Anika Therapeutics, Inc. lost $10 for every $100 of revenue.
Cash vs debt
Net cashAnika Therapeutics, Inc. held $31 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Anika Therapeutics, Inc.: $282 M ÷ $137 M (30 Jun 2026) = 2.1.
What is Anika Therapeutics, Inc.'s return on equity?
Anika Therapeutics, Inc. lost 2.2% of its shareholders' money over the last year, higher than 74% of Healthcare companies in United States.
How much does Anika Therapeutics, Inc. owe compared with what it owns?
Anika Therapeutics, Inc. owes $0.25 for every $1 it owns (low), lower than 66% of Healthcare companies in United States.
Does Anika Therapeutics, Inc. pay a dividend?
No. Anika Therapeutics, Inc. does not currently pay a dividend.
Is Anika Therapeutics, Inc.'s revenue growing?
Revenue fell 6% in the year to Dec 2025, and shrank 0% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.